WASHINGTON (AP) — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday. The ...

Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax stock was up on Monday amid roiling uncertainty about its Covid-19 vaccine approval, which has been caught up in the turbid health politics of the second Trump administration.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine is sowing uncertainty about other vaccines, too.

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older.

FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George's University hospital in ...

WASHINGTON — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 ...

A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George’s University hospital in London, Oct. 7, 2020. (AP Photo/Alastair Grant, File) ...

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older.